$BMY

$61.89▲ +4.6% YTD

8 SEC 13D/G filings tracked · Last updated Oct 12, 2026

Filing History

BMY ▲ +4.6% - Bristol-Myers Squibb Company

CP $61.89▲ +4.6%Oct 12, 2026 · ThinkSabio Blog

$BMY Bristol Myers Squibb: Phase 3 ALOFT-IPF Trial of Admilparant Meets Primary Endpoint at 60 mg Dose ? • 60 mg twice-daily dose showed a statistical…

News

BMY ▲ +4.6% - Bristol-Myers Squibb Company

CP $61.89▲ +4.6%Oct 12, 2026 · ThinkSabio Blog

$BMY Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint…

News

BMY ▲ +0.2% - Bristol-Myers Squibb Company

CP $59.77▲ +0.2%Oct 8, 2026 · ThinkSabio Blog

$BMY Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-…

News

BMY ▼ -2.1% - Bristol-Myers Squibb Company

CP $62.54▲ -2.1%Sep 29, 2026 · ThinkSabio Blog

$BMY new lows…

News

BMY ▼ -2.1% - Bristol-Myers Squibb Company

CP $62.54▲ -2.1%Sep 29, 2026 · ThinkSabio Blog

$BMY moving down…

News

BMY ▲ +0.6% - Bristol-Myers Squibb Company

CP $61.94▲ +0.6%Sep 25, 2026 · ThinkSabio Blog

$BMY Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RR…

News

BMY ▼ -0.9% - Bristol-Myers Squibb Company

CP $66.25▲ -0.9%Sep 8, 2026 · ThinkSabio Blog

$BMY Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-D…

SEC 13D/G

BMY - Bristol-Myers Squibb Company - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks Simplified

$64.04▲ 19.75%Aug 7, 2026 · ThinkSabio Blog

$BMY SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #BMY Bristol-Myers Squibb Company : $64.04 Sector: Healthcare | Y…